» Articles » PMID: 37699890

Previous Immunity Shapes Immune Responses to SARS-CoV-2 Booster Vaccination and Omicron Breakthrough Infection Risk

Abstract

The heterogeneity of the SARS-CoV-2 immune responses has become considerably more complex over time and diverse immune imprinting is observed in vaccinated individuals. Despite vaccination, following the emergence of the Omicron variant, some individuals appear more susceptible to primary infections and reinfections than others, underscoring the need to elucidate how immune responses are influenced by previous infections and vaccination. IgG, IgA, neutralizing antibodies and T-cell immune responses in 1,325 individuals (955 of which were infection-naive) were investigated before and after three doses of the BNT162b2 vaccine, examining their relation to breakthrough infections and immune imprinting in the context of Omicron. Our study shows that both humoral and cellular responses following vaccination were generally higher after SARS-CoV-2 infection compared to infection-naive. Notably, viral exposure before vaccination was crucial to achieving a robust IgA response. Individuals with lower IgG, IgA, and neutralizing antibody responses postvaccination had a significantly higher risk of reinfection and future Omicron infections. This was not observed for T-cell responses. A primary infection before Omicron and subsequent reinfection with Omicron dampened the humoral and cellular responses compared to a primary Omicron infection, consistent with immune imprinting. These results underscore the significant impact of hybrid immunity for immune responses in general, particularly for IgA responses even after revaccination, and the importance of robust humoral responses in preventing future infections.

Citing Articles

JN.1 variants circulating in Italy from October 2023 to April 2024: genetic diversity and immune recognition.

Giombini E, Schiavoni I, Ambrosio L, Lo Presti A, Di Martino A, Fiore S BMC Infect Dis. 2025; 25(1):291.

PMID: 40022017 PMC: 11871800. DOI: 10.1186/s12879-025-10685-0.


Lessons for medical countermeasure development from unforeseen outbreaks.

Mura M, Trignol A, Le Dault E, Tournier J Emerg Microbes Infect. 2025; 14(1):2471035.

PMID: 39976365 PMC: 11894751. DOI: 10.1080/22221751.2025.2471035.


Unraveling the impact of SARS-CoV-2 mutations on immunity: insights from innate immune recognition to antibody and T cell responses.

Bayarri-Olmos R, Sutta A, Rosbjerg A, Mortensen M, Helgstrand C, Nielsen P Front Immunol. 2024; 15:1412873.

PMID: 39720734 PMC: 11666439. DOI: 10.3389/fimmu.2024.1412873.


Effect of XBB.1.5-adapted booster vaccination on the imprinting of SARS-CoV-2 immunity.

Pusnik J, Monzon-Posadas W, Osypchuk E, Dubiel A, Baum M, Fehring P NPJ Vaccines. 2024; 9(1):231.

PMID: 39572559 PMC: 11582569. DOI: 10.1038/s41541-024-01023-7.


Seroprevalence of SARS-CoV-2 antibodies in children with nephrotic syndrome and chronic kidney disease: a cross-sectional study from India.

Singh R, Mantan M, Mahajan A, Tyagi V, Goswami B Pediatr Nephrol. 2024; 40(2):441-447.

PMID: 39327265 DOI: 10.1007/s00467-024-06534-y.


References
1.
Sheikh-Mohamed S, Isho B, Chao G, Zuo M, Cohen C, Lustig Y . Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection. Mucosal Immunol. 2022; 15(5):799-808. PMC: 9037584. DOI: 10.1038/s41385-022-00511-0. View

2.
McCarthy M . Original antigen sin and COVID-19: implications for seasonal vaccination. Expert Opin Biol Ther. 2022; 22(11):1353-1358. DOI: 10.1080/14712598.2022.2137402. View

3.
B Gilbert P, Montefiori D, McDermott A, Fong Y, Benkeser D, Deng W . Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2021; 375(6576):43-50. PMC: 9017870. DOI: 10.1126/science.abm3425. View

4.
Tan S, Kwan A, Rodriguez-Barraquer I, Singer B, Park H, Lewnard J . Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. Nat Med. 2023; 29(2):358-365. PMC: 9974584. DOI: 10.1038/s41591-022-02138-x. View

5.
Voldstedlund M, Haarh M, Molbak K . The Danish Microbiology Database (MiBa) 2010 to 2013. Euro Surveill. 2014; 19(1). DOI: 10.2807/1560-7917.es2014.19.1.20667. View